Ruti Aga: Marathon Runner Gets Six-Year Ban After Family Member's Forged Prescription Fatal to Her Defense

Ruti Aga: Marathon Runner Gets Six-Year Ban After Family Member's Forged Prescription Fatal to Her Defense

Key Points

• Ethiopian marathoner Ruti Aga, 32, has been banned for six years by the Athletics Integrity Unit (AIU).
• The ban is split into two parts: two years for the in-competition presence of methylprednisolone, and four years for tampering with the investigation through a forged prescription.
• The substance has been widely described in media reports as a "prohibited steroid." Technically, this is incorrect: methylprednisolone is a glucocorticoid, falling under Class S9 of the WADA Prohibited List, and it is prohibited in-competition only.
• Aga claimed she used the drug to treat a knee injury, but the prescription was issued by a family member who was not a registered physician, and the clinic named on the prescription did not exist in the AIU's investigation.
• The ban runs from 10 September, backdated to the date of her provisional suspension. At 32, a six-year ban means a return at roughly 38 — effectively career-ending given the depth of Ethiopian women's marathon running.
• Her 2026 Tokyo Marathon title and three World Marathon Majors second-place finishes remain part of her sporting record, but the result and prize money from the March race where the sample was collected are expected to be disqualified.

---

Introduction

The Athletics Integrity Unit (AIU) announced on Thursday that Ethiopian marathoner Ruti Aga has been banned for six years. The sanction is not the product of a single violation, but the sum of two connected cases: first, the detection of a prohibited substance, and second, the use of a forged prescription to justify its use.

As far as performance is concerned, the article offers very little. No official time, split, or field details from Aga's victory in a March half marathon in China are disclosed in the AIU statement. What is known is that she won the race and that an in-competition test detected the substance.

But the real centre of this story is not performance — it is administrative and legal process. And within that process lies a technical error that is being repeated in media coverage: the drug is being described as a "prohibited steroid," which is technically inaccurate. That is not just a language problem — it changes the entire legal direction of the case. So let us start with the technical clarification.

---

Part 1: What the Drug Is, and Why This Case Hinges on It

The drug found in Ruti Aga's sample is methylprednisolone. Media reports have called it an "anabolic steroid" or a "prohibited steroid." Technically, this is wrong. Methylprednisolone is a glucocorticoid, typically used to reduce inflammation — for joint inflammation, arthritis, or knee swelling. It has no connection to anabolic steroids (such as testosterone or nandrolone), which are known for muscle-building and which fall under Class S1.

In the WADA Prohibited List, glucocorticoids are placed in Class S9. And here is the crucial point: S9 substances are prohibited in-competition only. That means if an athlete takes them out-of-competition for a legitimate medical need, it is entirely legal — provided no residue remains in the body at the time of competition.

Any glucocorticoid administered by injection, orally, or rectally is prohibited in-competition. A knee injection — a common therapeutic procedure among marathon runners — is entirely valid if administered sufficiently before competition and properly documented.

This means Aga's defence could have followed a legitimate and legal path. If she had genuine medical records, a genuine doctor's prescription, a genuine clinic record, and a properly timed washout period — the case might never have been seriously recorded in athletics, or at least a "no fault" or "no significant fault" argument for the in-competition presence could have succeeded.

But what did she do? She had a fake prescription made. And that is the decisive turn in the entire case.

---

Part 2: What Happened — The Sequence of Events

According to the AIU investigation, the sequence is as follows:

March, China: Aga competed in and won a half marathon in China. Her sample was collected during the in-competition testing at that race. The sample showed traces of methylprednisolone.

The knee injury claim: Aga stated she had a knee injury for which she took the medication.

Investigation of the prescription: When the AIU examined the source of the prescription, it found that it had been issued by a family member who was not a registered physician. That person claimed to have used "an old prescription pad from a former workplace." But the clinic named on the prescription — according to the AIU's investigation — did not exist.

First charge — Presence: Two-year ban. This is typically imposed when the athlete's intent is not proven, or when the substance falls under the Specified Substance category and the athlete has not successfully argued "No Significant Fault or Negligence."

Second charge — Tampering: Four-year ban. This is because submitting a forged prescription and providing misleading information to an investigating agency was sanctioned as "tampering." This is a separate and serious offence under the WADA Code, with a standard four-year sanction.

Total: Six years. The ban was applied from 10 September — the same date as the provisional suspension — meaning that time already served during the investigation counts against the ban. This is a procedural benefit, not a reduction.

---

Part 3: The Six-Year Arithmetic — 2 + 4 = 6

It is important to understand that a six-year ban is not unusual in sports jurisprudence. It is the sum of two standard sanctions:

| Charge | Sanction | Rationale | |------|------|------| | Presence of prohibited substance (S9 glucocorticoid, in-competition) | 2 years | Intent not proven, but negligence or improper process | | Tampering — forged prescription, misleading statements | 4 years | Standard WADA Code sanction | | Total | 6 years | Two separate but connected offences |

This arithmetic reveals an important fact: the panel rejected the mitigation available under "No Significant Fault." Had Aga produced genuine medical records, the presence sanction could likely have been reduced to a year or less. But by submitting a forged prescription, she destroyed her own strongest defence.

The interesting paradox is that forged documents are themselves circumstantial evidence of concealment intent — yet they did not increase the presence sanction, but were separately penalised as tampering. In other words, the panel treated them as independent offences.

It is also worth noting that the ban is backdated to 10 September, but that is not a "discount." It simply reflects that the athlete was provisionally suspended from that date and the actual ban is counted from it. This also means that the time spent in investigation is included — it provides no practical benefit to the athlete.

---

Part 4: Career Impact — From 32 to 38

Ruti Aga is currently 32. A six-year ban means her next opportunity to race will come at roughly 38. In women's marathon, particularly given the depth of competition in a country like Ethiopia, a return at 38 after a six-year doping ban is, in practice, the end of a career.

Ethiopian women's marathon is so deep that even a 2:18-level runner cannot be certain of a national team place. A 38-year-old who has been out of the sport for six years, and who has a doping record against her name, has virtually no chance of national selection.

Aga's 2026 Tokyo Marathon win and three World Marathon Majors second-place finishes demonstrate her class. She was a genuinely top-level marathoner. But this ban completely ends her participation in the 2028 Olympic cycle — and beyond that, because a return at 38 to high-level performance is virtually closed.

Moreover, because the ban starts from 10 September, her 2026 title and earlier results will not be automatically annulled — unless the investigation establishes earlier use of the prohibited substance. But the result and prize money from the March race where the sample was collected are very likely to be disqualified, since standard AIU procedure automatically disqualifies the competition where the sample was collected, and any ranking points earned from it are forfeited.

---

Part 5: The 2026 Tokyo Marathon — What Remains

Aga's greatest career achievement is the 2026 Tokyo Marathon title. That was at a time when she was at her peak. She also has three World Marathon Majors second-place finishes to her name.

This ban will not affect those results, since the case is connected to a later race. The AIU statement does not specify the year of the race, but the references to "provisional suspension from 10 September" and "statement on Thursday" suggest the event is from the current year.

That means: historically, the 2026 Tokyo Marathon win and three Major podium finishes will remain part of her sporting record. But commercially, she is now "controversial" — and marathon running sponsorship is already thin, even more so after a ban.

The "career value" angle is also interesting. The 2026 title gave her global recognition, but subsequent results — three Major second places — could not complete that final step. And now, with the ban, her legacy assessment is split into two parts: on one hand the 2026 win and three Major podiums; on the other, a six-year doping ban.

---

Part 6: Medical Governance Failure — The Real Root of the Case

This case is not just one athlete's mistake. It exposes a systemic failure of medical governance in East African road running.

First: the prescription was issued by a family member who was not a registered physician. Any professional athlete should have a qualified team physician who treats injuries and understands the rules on prohibited substances. In Aga's case, that role was filled by a relative who was not a physician.

Second: the clinic named on the prescription did not exist. That is a serious revelation — it means the athlete was being treated at places that were not real, or were fabricated on paper.

Third: there was no TUE (Therapeutic Use Exemption) arrangement. A properly managed athlete would either hold or apply for a TUE, or ensure a correct washout period before competition. Neither happened.

From these three failures, a pattern emerges: Aga did not have a professional, certified medical team. What she had was an informal network — family, friends, or a local "doctor" — who understood paperwork but not the rules.

This is not just Aga's personal problem. In East African road running there is an entire ecosystem where medical support for top marathoners is often informal. Relationships between agents, coaches, family, and local clinics are characterised by a lack of transparency and accountability. And when an athlete is injured, they go for the fastest, cheapest option — a glucocorticoid injection is the easiest and most available.

This means Aga's case is not an isolated incident. It is part of a wider problem in a stratum of the sport where runners — whose income is largely driven by "appearance fees" — want to race even when injured, because no race means no money. Under this pressure, they compromise on both medicine and administration.

---

Part 7: The AIU's Role and the New Frontier of Document Verification

The Athletics Integrity Unit (AIU) was created in 2026 to investigate corruption, doping, and other integrity cases in athletics. It operates independently and enforces World Athletics rules.

In this case, the AIU's role is two-fold: first, identifying the presence of a prohibited substance in the sample; second, verifying the truth of the explanation and documents provided.

That second role is increasingly becoming a major part of AIU's work. The centre of anti-doping enforcement is no longer just "detection" but "document verification." When an athlete claims to have taken a drug, the AIU does not simply rely on the claim — it independently verifies prescriptions, clinics, doctors' registrations, and medical records.

In Aga's case, all three verifications failed: the clinic did not exist, the doctor was unregistered, and the "old prescription pad" claim was explicitly disowned by the clinic.

This is a major signal: athletes caught submitting forged documents face sanctions not only for the substance but also for tampering — and that is often greater than the original sanction.

Furthermore, this case shows that the AIU also uses interviews in its investigations — that is, the athlete's statements. Part of Aga's four-year sanction is connected to the fact that what she said under questioning was found to be misleading. Language and translation issues in AIU interviews with Ethiopian athletes have been a recurring point of contention — is this a procedural fairness issue? That is debatable, but under current rules the AIU has the power.

---

Part 8: China's Label Races and the East African Runners' "Income Mine"

Aga's sample was collected at a March half marathon in China. The AIU statement does not name the race, but it indicates it was a World Athletics Label road race — with an international-standard elite women's field and in-competition testing facilities.

In recent years, label races in China — especially half marathons — have become a major source of income for East African runners. Large prizes, high appearance fees, and low competition make these races very attractive. For a 2:18-2:20 level marathoner, this is a tier where they can earn extra income between Majors.

But this same tier has now become the AIU's most "fertile" testing ground. Big money attracts and AIU surveillance collide in the same races. It is no coincidence that the number of doping cases caught at Chinese label races is rising.

For Aga, that March race became the greatest irony of her career — the race she won became the beginning of her downfall.

---

Part 9: Ethiopian Marathon Depth and the Impact of the Ban

Ethiopia is the greatest force in women's marathon running. A large number of the world's fastest women marathoners are Ethiopian. Tokyo, Berlin, London, Chicago — every major marathon features Ethiopian dominance.

That depth means: the departure of one athlete does not in any way affect the capacity of the national team. Aga's post-2026 results — three Major second places — are commercially important, but for the national team they did not convert into "World Championship medals."

In other words, this ban does not damage Ethiopian marathon strength. It only ends one individual career — which is certainly huge for that individual, but not for the overall sporting landscape.

Instead, the real concern is the sport's integrity regime. In East African countries — Ethiopia and Kenya — AIU involvement in road-running cases is consistently increasing, and a pattern is forming that shows the administrative side of the sport to be weak.

---

Part 10: TUE — The System That Was Never Used

The most striking aspect of this whole case is that a straightforward medical procedure (a glucocorticoid injection in the knee) had a legitimate path, but it was not taken.

A TUE — Therapeutic Use Exemption — is a system under which an athlete can seek permission to take a medication that is normally prohibited, provided it is necessary for medical need and there is no alternative treatment.

If Aga had a qualified physician, she could have: 1. Applied for a TUE (if the drug was needed during competition as well) 2. Or, more likely, taken the drug sufficiently before competition so that no residue remained at competition time 3. Or, if the drug had to be taken during competition, followed a proper medical procedure

Because none of this happened, and instead a forged prescription was created, it shows that the athlete was either unaware of the TUE process or lacked a professional adviser to handle it.

This is a systemic failure. An athlete should not have to know what a TUE is and how to apply — their agent, manager, or team doctor should. But in East African road running, many athletes lack such a support structure.

---

Part 11: What Could Have Been Saved — A Counterfactual Analysis

If everything had been done correctly, Aga's career would still be ongoing. An approximate "best case" looks like this:

Best case: Correct medical procedure + TUE or proper washout + drug taken sufficiently before competition → no charges at all.

Intermediate case: Genuine medical records + drug taken at the edge of proper washout → "No Fault or No Significant Fault" defence on the presence charge, potentially reducing the sanction to one year or less, and no tampering charge.

Worst case (what happened): Forged prescription + misleading statements → 2 years + 4 years = 6 years, plus the March race result and prize money disqualified.

This clearly shows that the direction of the entire case was changed by one thing: the forged prescription. Not the drug, but the "cover-up" attempted to justify its use.

This is a general lesson every athlete should understand: in anti-doping investigations, detection of a drug is one thing, but telling the truth and following proper process afterwards is even more important. Lying or submitting forged documents does not reduce a sanction — it increases it.

---

Part 12: Appeal Status

After the AIU statement, an athlete usually has the option to appeal to the Court of Arbitration for Sport (CAS). The time limit is typically around 21 days from receipt of the reasoned decision.

But in this case, the chances of a successful appeal are low, because: 1. Evidence of the substance's presence is solid (the sample) 2. All three verifications of the forged prescription failed (no clinic, no registered doctor, clinic disowned the prescription) 3. The sanction calculation (2 + 4) is consistent with the standard Code

A possible basis for appeal could be: language/translation issues in the interview or procedural irregularities. But that is a weak basis.

In addition, document forgery could also constitute a criminal matter, which falls outside the AIU's jurisdiction. Whether it will be referred to national authorities is unclear, but the possibility remains.

---

Part 13: The Pattern of Other Cases

Aga's case is not unique. In recent years, several AIU cases have emerged against East African (particularly Ethiopian and Kenyan) road-running athletes, where an initial substance violation was followed by an attempt to provide a forged or altered explanation. This has become a recognisable "pattern":

1. The athlete is caught at a race
2. The athlete offers an explanation (injury, illness, accidental medication)
3. The AIU requests documentation
4. Documents are produced, but their authenticity is suspect
5. Investigation reveals the documents are forged or altered
6. The athlete is charged with tampering and the sanction increases

This pattern indicates that the "entourage" working around these athletes has become adept at producing such documents. It is a network that knows how to use an old prescription pad, how to write a clinic's name, how to name a doctor. But the AIU is now beginning to recognise these methods.

It is possible that several similar cases are currently in the pipeline, because athletes in the same training group or region often share the same kind of informal medical network.

---

Part 14: Lessons for the Future

Several lessons emerge from this case:

For athletes: - Consult a qualified, registered physician for any medical treatment. - Before taking a drug, check its prohibited status (WADA Prohibited List). - If a drug is necessary, follow the TUE process. - Never submit forged documents — it can lead to a sanction greater than the original offence.

For agents and managers: - Athletes should have a certified medical team. - Medical records should be securely maintained. - Athletes should be informed about anti-doping rules.

For organisations (national federations, AIU, WADA): - Education and awareness programmes should be expanded in the East African road-running region. - The Athlete Support Programme should be strengthened. - Medical support should be made available at the local level.

---

Part 15: Conclusion

Ruti Aga's case is a reflection of a sports system where there is enormous talent but weak administration. A 32-year-old marathoner who won the 2026 Tokyo Marathon and finished second at three World Marathon Majors got caught in a mistake that could have been avoided.

Two years for the presence of the drug and four years for the forged prescription — this six-year arithmetic is consistent with sports jurisprudence. But the human story behind it is that an injured athlete, lacking proper medical support, chose the easiest path — and that path ended her career.

One thing this case makes clear: in modern anti-doping enforcement, detection of a drug is not the biggest problem. What happens afterwards is often more decisive. Aga lost a valid defence on the substance because, instead of telling the truth, she had a false document created.

This is not just one athlete's story. It is the story of a system in East African road running that produces talent but does not provide the professional structure needed to manage it. And until that structure exists, cases like this will continue.